Literature DB >> 2844711

Enzymatic and chemical modifications of lipopeptide antibiotic A21978C: the synthesis and evaluation of daptomycin (LY146032).

M Debono1, B J Abbott, R M Molloy, D S Fukuda, A H Hunt, V M Daupert, F T Counter, J L Ott, C B Carrell, L C Howard.   

Abstract

The novel lipopeptide antibiotic A21978C complex is active against Gram-positive organisms. This complex consists of a common peptide nucleus with various lipid acyl groups at the N-terminus characteristic of each individual factor. The fatty acid acyl group is removed by incubation of the A21978C complex with Actinoplanes utahensis to give the peptide nucleus. This peptide nucleus has the same amino acid sequence as A21978C. New analogs of A21978C were synthesized by acylation of the N-terminus of a tert-butoxycarbonyl (tert-BOC)-protected nucleus and subsequent deprotection. 1H NMR showed that the newly introduced acyl group was at the desired N-terminus. Three major groups of analogs were synthesized bearing fatty acid acyl, amino-aroyl and extended peptide side chains. Each analog was evaluated for antimicrobial activity and acute toxicity. Of these analogs, the n-decanoyl analog of A21978C (LY146032) gave the best survival in the mouse acute toxicity test at a high dose of 1,000 mg/kg, iv and was chosen for further study. This analog has been named daptomycin.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844711     DOI: 10.7164/antibiotics.41.1093

Source DB:  PubMed          Journal:  J Antibiot (Tokyo)        ISSN: 0021-8820            Impact factor:   2.649


  46 in total

1.  Inactivation of the lipopeptide antibiotic daptomycin by hydrolytic mechanisms.

Authors:  Vanessa M D'Costa; Tariq A Mukhtar; Tejal Patel; Kalinka Koteva; Nicholas Waglechner; Donald W Hughes; Gerard D Wright; Gianfranco De Pascale
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

Review 2.  Nonribosomal peptide synthetases involved in the production of medically relevant natural products.

Authors:  Elizabeth A Felnagle; Emily E Jackson; Yolande A Chan; Angela M Podevels; Andrew D Berti; Matthew D McMahon; Michael G Thomas
Journal:  Mol Pharm       Date:  2008-01-25       Impact factor: 4.939

3.  Mechanisms of resistance to daptomycin in Enterococcus faecium.

Authors:  Clemente I Montero; Frida Stock; Patrick R Murray
Journal:  Antimicrob Agents Chemother       Date:  2008-01-07       Impact factor: 5.191

4.  Isolation and structure elucidation of lipopeptide antibiotic taromycin B from the activated taromycin biosynthetic gene cluster.

Authors:  Kirk A Reynolds; Hanna Luhavaya; Jie Li; Samira Dahesh; Victor Nizet; Kazuya Yamanaka; Bradley S Moore
Journal:  J Antibiot (Tokyo)       Date:  2017-11-29       Impact factor: 2.649

5.  Molecular cloning and physical mapping of the daptomycin gene cluster from Streptomyces roseosporus.

Authors:  M A Mchenney; T J Hosted; B S Dehoff; P R Rosteck; R H Baltz
Journal:  J Bacteriol       Date:  1998-01       Impact factor: 3.490

6.  Structural and dynamic characterization of a freestanding acyl carrier protein involved in the biosynthesis of cyclic lipopeptide antibiotics.

Authors:  Subrata Paul; Hiroaki Ishida; Leonard T Nguyen; Zhihong Liu; Hans J Vogel
Journal:  Protein Sci       Date:  2017-03-01       Impact factor: 6.725

7.  Isolation of a Paenibacillus sp. strain and structural elucidation of its broad-spectrum lipopeptide antibiotic.

Authors:  Yaoqi Guo; En Huang; Chunhua Yuan; Liwen Zhang; Ahmed E Yousef
Journal:  Appl Environ Microbiol       Date:  2012-02-24       Impact factor: 4.792

Review 8.  Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery.

Authors:  Lars Robbel; Mohamed A Marahiel
Journal:  J Biol Chem       Date:  2010-06-03       Impact factor: 5.157

Review 9.  A current perspective on daptomycin for the clinical microbiologist.

Authors:  Romney M Humphries; Simon Pollett; George Sakoulas
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  [Resistance to "last resort" antibiotics in Gram-positive cocci: The post-vancomycin era].

Authors:  Sandra Rincón; Diana Panesso; Lorena Díaz; Lina P Carvajal; Jinnethe Reyes; José M Munita; César A Arias
Journal:  Biomedica       Date:  2014-04       Impact factor: 0.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.